Nerandomilast slows FVC decline in progressive pulmonary fibrosis
1. In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients ...
Tag: pulmonology
Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence
1. In this retrospective cohort study, the presence of tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of ...
Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
1. In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, sotatercept reduced ...
Mepolizumab decreases exacerbations in patients with eosinophilic COPD
1. In this randomized controlled trial, mepolizumab decreased the annualized rate of moderate or severe exacerbations when added to triple ...
Poor baseline lung function associated with increased risk of incident tuberculosis
1. The risk of tuberculosis (TB) was higher in individuals with obstructive or restrictive lung function impairment compared to those ...
Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial hypertension ...
Depemokimab therapy reduces exacerbations in patients with severe eosinophilic asthma
1. In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients with severe eosinophilic asthma. ...
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term benefits by reducing ...
Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease
1. In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was not associated with improved clinical ...
AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited-stage small cell lung cancer
1. Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. ...
